{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:52:44Z","timestamp":1790175164211,"version":"4.1.0"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We recently observed that the micafungin MICs for some\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida glabrata fks<\/jats:named-content>\n            hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">C. glabrata<\/jats:named-content>\n            isolates with or without (S3)\n            <jats:italic>fks<\/jats:italic>\n            hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E\n            <jats:sub>50<\/jats:sub>\n            s) were 194.2 and 53.99 mg \u00b7 h\/liter, respectively. In contrast, the maximum effect (\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) for caspofungin was higher against S3 than R83, but the estimates for E\n            <jats:sub>50<\/jats:sub>\n            were similar (187.1 and 203.5 mg \u00b7 h\/liter, respectively). Anidulafungin failed to induce a \u22651-log reduction for any of the isolates (AUC range, 139 to 557 mg \u00b7 h\/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.\n          <\/jats:p>","DOI":"10.1128\/aac.06369-11","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T02:37:05Z","timestamp":1329878225000},"page":"2435-2442","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":113,"title":["Differential\n            <i>In Vivo<\/i>\n            Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without\n            <i>FKS<\/i>\n            Resistance Mutations"],"prefix":"10.1128","volume":"56","author":[{"given":"Maiken Cavling","family":"Arendrup","sequence":"first","affiliation":[{"name":"Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, UMDNJ-New Jersey Medical School, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Hare","family":"Jensen","sequence":"additional","affiliation":[{"name":"Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Julie","family":"Howard","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Goodwin","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01584-09"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0b013e32833e84d2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01292-08"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-09"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01373-10"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01364-10"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00179-11"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm095"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir351"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02072-06"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01711-09"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-07"},{"key":"e_1_3_2_14_2","volume-title":"CLSI document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard\u2014third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","volume-title":"CLSI document M44-A2","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline\u2014second edition. CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_16_2","volume-title":"Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis","author":"Dannaoui E","year":"2010","unstructured":"DannaouiE. 2010. Infections due to Candida spp. with reduced susceptibility to caspofungin in France, abstr. O346. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00088-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jn\/3.3.289","article-title":"The determination of the surface area of the white rat","volume":"3","author":"Diack SL","year":"1930","unstructured":"DiackSL. 1930. The determination of the surface area of the white rat. J. Nutr. 3:289\u2013296.","journal-title":"J. Nutr."},{"key":"e_1_3_2_19_2","unstructured":"Ecalta. 2011. Ecalta: EPAR product information. European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000788\/WC500020673.pdf."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000238186","article-title":"The pneumococcus and the mouse protection test: importance of the lag phase in vivo","volume":"29","author":"Frimodt-Moller N","year":"1983","unstructured":"Frimodt-MollerN SebbesenO FrolundTV. 1983. The pneumococcus and the mouse protection test: importance of the lag phase in vivo. Chemotherapy 29:128\u2013134.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-08"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00443-09"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01162-08"},{"key":"e_1_3_2_24_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-352","author":"Garcia-Effron G","year":"2009","unstructured":"Garcia-EffronG ParkS PerlinDS. 2009. Improved Candida spp. echinocandin susceptibility determination by the addition of bovine serum albumin (BSA). Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-352."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1331-1336.2005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00621-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00349-06"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/500939"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60605-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl022"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.877"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3264-3273.2005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm453"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.04.002"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.09.002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-06"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02390-09"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066906"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01935.x"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01686-10"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.739-745.2002"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.8.1155"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06369-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06369-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:55:13Z","timestamp":1645480513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.06369-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1128\/AAC.06369-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.06369-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"2011-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}